Life Sciences Partners, an Amstadam-based life sciences investor, has closed a $600 million fund after reaching its hard cap. The fund, LSP 6, is the largest fund ever raised in Europe focused on life sciences ventures. 

LSP currently has $1.1 billion of capital to invest across LSP 6, the LSP Health Economics Fund and LSP’s public fund and mandates.

LSP 6 is aiming to invest in 15 to18 predominantly European private companies developing new medications or medical technologies.

The firm has built more than 120 companies which have brought new medications and technology for oncology, cardiology, diabetes and rare diseases. 

LSP managing partner René Kuijten said: “We thank our loyal investors for their continued trust in LSP. Our track record, our long-standing in the industry, as well as our stable and experienced team of 30 professionals have helped us raise this significant amount. The number of high-quality life sciences innovations in Europe is similar to the US but there is five times less capital available to back these innovators and entrepreneurs. With our new fund we can significantly contribute to the growth of our industry and ensure that European innovations get to patients faster.”

Date published: March 12, 2020

Subscriber content

To get unlimited access subscribe today


Already a subscriber? Login